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Eugenol has been employed for decades as a condiment, an antimycotic, an antibacterial, an antiviral, and 
an antioxidant, and it is one of the natural analgesics most frequently utilized for pain and inflammation. 
Our objective was to determine the analgesic/anti-inflammatory effect of eugenol compared with 
diclofenac, naproxen, and tramadol using the formalin test. The formalin method was used in 6- to 
10-week-old Wistar rats (weighing 250 g each) divided into six groups: saline (0.9%); formalin (5%); 
diclofenac (250 µg/kg); naproxen (400 µg/kg); tramadol (500 µg/kg), and eugenol (1,400 µg/kg), in 
the intraplantar part of the hind-end trunk of the rats, with n = 5 per group. Eugenol diminished 44.4% 
of nociceptive behavior in phase 1 and 48% in phase 2 (p ≤0.05 vs formalin). Eugenol was shown to 
be 1.14 times more effective than diclofenac, but 1.62 and 1.75 times less effective than naproxen and 
tramadol, respectively, in phase 1 and 1.45 times less effective than diclofenac and naproxen and 1.66 
less effective than tramadol in phase 2 (p ≤0.05). These data suggest that eugenol possesses moderate 
activity in the acute pain phase and greater activity in inflammatory-type pain, and both effects are 
comparable to those produced by diclofenac and are less than the effects produced by naproxen and 
tramadol in the formalin test.
Keywords: Eugenol/analgesic/anti-inflammatory effect. Diclofenac effect. Antinociception. Formalin 
test. Pain. 
INTRODUCTION
For centuries, popular culture has utilized plant 
extracts to alleviate a wide range of pathologies, 
principally pain. Thus, according to a World Health 
Organization (WHO) report, between 70 and 80% of the 
world population depends on some herbal sources as their 
main therapeutic option (OMS, 2012).
Eugenol (4-allyl-2-methoxyphenol; C10H12O2) 
is a natural product with broad therapeutic properties 
that is extracted from Eugenia cariophyllata and other 
plants. Eugenol belongs to the phenlypropanoid family 
and has a molecular weight (MW) of 164.2 g/mol with a 
pKa = 10.19 at 25°C (Charan-Raja et al., 2015). This plant 
has been used as an antioxidant (it inhibits the generation 
of active oxygen species in endothelial cells), antimycotic, 
antiviral, antiparasitic, antibiotic, and in deinsectation 
(Kong et al., 2014c). Studies in humans have shown that 
eugenol possesses antiplatelet activity due to the inhibition 
of cyclooxygenase (COX)-dependent thromboxane A2 
(TXA2) (Raghavendra and Naidu, 2009). It has been 
considered to be an anti-inflammatory agent due to its 
participation in the inhibition of cyclooxygenase type 2 
(COX2) expression and, consequently, of prostaglandins 
(PG), which are derived from COX2 (Murakami et 
al., 2012). PG and leukotrienes (LT) are mediators of 
the inflammatory response; thus, they increase blood 
flow and vascular permeability and, at physiological 
concentrations, sensitize nerve endings and attenuate pain 
and inflammation (Faezeh et al., 2015). iD
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It has been noted that eugenol at low concentrations 
exerts a reducing effect on synaptic transmission of the 
neuromuscular zone, thus being capable of producing 
anesthesia (Charan-Raja et al., 2015). However, Dal Bó 
and colleagues (2013) demonstrated that the analgesic 
mechanism of action can involve the opioid system, 
glutaminergic receptors (Kainate and AMPA), and 
the inhibition of tumor necrosis factor alpha (TNF-α); 
therefore, it can be an important component in the 
treatment of acute pain. 
In models of pain and inflammation, eugenol 
has demonstrated its effectiveness in the diminution of 
behavior induced by acetic acid and the hot-fire platelet 
test in mice to an extent comparable with the effects of 
celecoxib and indomethacin (Apparecido et al., 2009). 
Moreover, eugenol is effective in some treatments for 
dental alveolar osteitis, presentations of pastes that contain 
a vegetal fiber impregnated with iodoform, butoform, 
eugenol, olive oil, and a topical anesthetic (Morales, 2011). 
Among some of the applications in the pharmaceutical 
industry, we can highlight topical creams and emulsions 
for the oral administration of medicaments used as topical 
and oral anesthesia (Hu, Arocha, Pineda, 2014). One of the 
specialties that has the most experience in the use of eugenol 
is odontology, given that it has played a very important role 
in dental preparations applied on deep cavities (Pavithra, 
2014). An example of this is the use of the zinc oxide/
eugenol (ZOE) combination, which is frequently employed 
as obturation material in the treatment of pulpotomy and 
pulpectomy in temporary dentition (Fucks and Peretz, 2016; 
González-Lara et al., 2014). The aim of this work was to 
determine the antinociceptive activity of eugenol compared 
with diclofenac, naproxen, and tramadol by the formalin 
method in rats.
MATERIAL AND METHODS
Reagents
Sterile saline solution at 0.9% (NaCl) (Thermo 
Fisher Scientific), formaldehyde solution (37 wt.% in 
H2O) (Sigma-Aldrich), eugenol at 99% (eq. 100 g) 
(Sigma-Aldrich), injectable diclofenac solution (15 mg/3 
mL) (Novartis Laboratories), naproxen ≥98% (Sigma 
Aldrich), and tramadol chlorhydrate ≥98% (Sigma 
Aldrich) were used.
Animals
We utilized male Wistar rats 6 to 8 weeks of age, 
with an approximate weight of 250 g each, which were 
acclimatized at a regulated temperature of 25°C with a 
12:12 h light:dark cycle and free access to food and water. 
Each experimental group consisted of n = 5. Once the tests 
were carried out, the animals were sacrificed according 
to the ethical guidelines for the investigation of pain in 
experimental animals of the International Association for 
the Study of Pain (IASP, 2014). The experimental models 
were maintained under standard bioterium conditions.
Measurement of nociceptive response
Prior to the experiment,  the animals were 
acclimatized for a 60-min period for 3 days and for 1 h 
prior to the experiment. Nociception was measured under 
the administration of formalin at 5% (50 µL) and the 
quantification of the number of paw flinches/shakes during 
1 h for 5-min periods in two phases: the first comprised 0 to 
15 min, and the second, 15 to 60 min. The antinociceptive 
effect was evaluated with the administration of the 
treatments 20 min before the intraplantar administration 
of formalin at 5%.
For evaluation of the analgesic effect of the drugs, 
we calculated the percentage of antinociception by means 
of the following formula: 
Experimental design
The animals were injected with a total solution of 
50 µL per experiment with the following concentrations: 
formalin 5%, saline solution 0.9%, eugenol 1,400 µg/kg, 
diclofenac 250 µg/kg, naproxen 400 µg/kg, and tramadol 
500 µg/kg, in independent groups and a volume of 25 µL 
at the local level in the intraplantar part of the hind-end 
trunk of the rats (Table I; proportion v/v). 
Statistical analysis
We calculated the average and standard error (SE) 
of each group with an n = 5 for the time courses; after this, 
we applied the Shapiro Wilks normality test, the one-way 
analysis of variance (ANOVA), followed by a post hoc 
Tukey test (p ≤0.05). All of the data were modeled using 
the Origin ver. 8.0 statistical software package.
RESULTS
Eugenol at a dose of 1,400 µg/kg during the first 15 
min produced a decrease of 10–30 paw flinches/shakes; 
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from 15 min to 60 min, there was a decrease of up to 
34 paw flinches/shakes with respect to the group with 
formalin 5% (p ≤0.05); see Figure 1(a). Administration 
of diclofenac (250 µg/kg), as seen in Figure 1(b), 
demonstrated a diminution from 28 to 12 paw flinches/
shakes at 15 min and from 12 to 5 paw flinches/shakes 
from min 15 to min 60 (p ≤0.05) vs. formalin 5%. The 
group with naproxen (400 µg/kg) presented 6–11 paw 
flinches/shakes from min 5 and remained at these values 
until min 60 of evaluation (p ≤0.05 vs. formalin 5%); see 
Figure 1(c). On administering tramadol (500 µg/kg), from 
min 5, we observed only 5–8 paw flinches/shakes, and this 
TABLE I - Distribution of experimental groups
Groups Treatments (µL) Formalina 5% (µL) Total volume (µL)
Formalin (control) – 50 50
Sol . saline (0.9%) 50 – 50
Diclofenac (250 µg/Kg) 25 25 50
Naproxen (400 µg/Kg) 25 25 50
Tramadol (500 µg/Kg) 25 25 50
Eugenol (1200 µg/Kg) 25 25 50
The treatments are administered twenty minutes before the administration of formalin 5 %.
FIGURE 1 - Time course of the formalin test to 5%, panel (a) represents the effect of Eugenol to 1,400 µg/kg, panel (b) is that of 
Diclofenac to 250 µg/kg, panel (c) Naproxen to 400 µg/kg, and panel (d) Tramadol to 500 µg/kg on intraplantar administration. 
The data represent the Ẋ ± SEM of an n = 5, while (*) represents a statistically significant difference vs. formalin at 5% (p ≤0.05).
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reduction was sustained until min 60 (p ≤0.05 vs. formalin 
5%); see Figure 1(d). 
On analyzing phase 1 (5–15 min) of the formalin 
test, we found that paw flinching/shaking behavior in rats 
diminished 38.8% for diclofenac (250 µg/kg), 72.2% for 
naproxen (400 µg/kg), 77.7% for tramadol (500 µg/kg), 
and 44.4% for eugenol (1,400 µg/g) (p ≤0.05) vs. the 5% 
formalin group. The diclofenac and eugenol groups had a 
similar behavior to the saline solution group (0.9%); see 
figure 2. 
In phase 2 of the formalin test, the behavior 
diminished 70% for diclofenac (250 µg/kg), 70% for 
naproxen (400 µg/kg), 80% for tramadol (500 µg/kg), and 
48% for eugenol (1,400 µg/kg), all significantly different 
from the saline group (0.9%) (p≤0.05) vs. formalin 5%; 
see figure 3. 
DISCUSSION
Non-steroidal anti-inflammatory drugs (NSAIDS) 
are considered first-choice analgesics for slight-to-
moderate pain; however, for moderate-to-severe pain, the 
joint use of NSAIDS and low-dose opioids is considered, 
according to WHO criteria in 2012. Additionally, mention 
has been made of the use of tramadol for slight-to-severe 
pain; however, in view of the natural-type therapeutic 
options, eugenol had been widely utilized within the 
empirical context by means of some scientific criteria, as in 
the case of odontology (Apparecido et al., 2009; Escobar-
Garcia et al., 2016). In this regard, Dal Bó and coworkers 
(2013) evaluated the effects of eugenol at 3–300 mg/kg, 
per os (p.o.) for 60 min, or intraperitoneally (i.p.) for 30 
min, finding that it inhibited 82 ± 10% and 90 ± 6% of 
nociceptive behavior, respectively, in the acetic acid acute 
pain model in mice. Our data reflect the decrease in the 
number of paw flinches/shakes as 48% with eugenol vs. 
the 5% formalin group (p ≤0.05), but from min 15 of the 
formalin test, as seen in figure 1(a), the behavior was more 
marked in inflammatory pain due to its effect in phase 2, 
as seen in figure 2, with a tendency to diminish the acute 
pain phase (44.4% without statistical significance, phase 
1 vs. formalin 5%); see figure 3. 
These data are also in agreement with those 
described by Apparecido and colleagues in 2009, in 
which the authors demonstrated that eugenol at an oral 
dose of 400 µg/kg presented antinociceptive effects in a 
carrageenan model. Eugenol diminished edema 2–4 h after 
the administration of carrageenan in 41.1% of subjects, 
very similar to the effect produced by indomethacin and 
celecoxib. Garcia de Alba Garcia and coworkers (2012) 
noted that eugenol likewise reduced synaptic transmission 
at the neuromuscular junction, where nerve fibers play 
an important role in the generation of the inflammatory 
response, because sensory nerves in dental pulp contain 
vasoactive peptides such as substance P (SP), the peptide 
related to the calcitonin gene, and others. For their part, 
Faezeh and colleagues (2015) reported that oil of clove 
is a potent inhibitor of thromboxane production and 
platelet aggregation in human blood in vitro: PG as 
well as leukotrienes (LT) are important mediators in the 
inflammatory response. 
The fact that eugenol effectiveness during phase 1 
of the formalin test was 44.4% and diclofenac was 38.8% 
(see figure 2) and that in phase 2, diclofenac effectiveness 
was 70% (see figure 3) and eugenol was 48% might 
be explained based on activity in the nervous system 
and on the vascular components of the inflammatory 
response. These results indicate a potential for eugenol 
FIGURE 2 - Graphic of the phase 1 of the formalin test, the 
data representing Ẋ ± SEM of an n = 5. *P ≤0.05 vs. the 5% 
formalin group.
FIGURE 3 - Graphic of the phase 2 formalin test, the data 
representing the Ẋ ± SEM of an n = 5; *P ≤0.05 vs. the 5% 
formalin group.
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as an analgesic as well as an anti-inflammatory, to an 
extent comparable with diclofenac and naproxen. In the 
literature, there are very few data in this regard. In this 
context, Yano and colleagues (2006) demonstrated that, 
in mice, methyleugenol (10 µg/kg) isolated from Asiasari 
radix significantly diminished the duration of paw licking 
and biting time in phase 2 of the formalin test without 
affecting phase 1. This behavior is similar to that found 
in our experiments for eugenol and comparable to that 
produced by diclofenac, which itself has demonstrated an 
effect in the formalin test (Picazo, Castañeda-Hernández, 
Ortiz, 2006) and the thermal model of inflammation 
(Hasani et al., 2011).
Within this context, eugenol presents a 1.62-times 
lesser effect in phase 1 (44.4 vs. 72.2%; see figure 2) and 
a 1.45-times lesser effect in phase 2 than naproxen (48 vs. 
70%; see figure 3). In this regard, Mendoza et al. (2013), 
in a rat model of osteoarthritis, found that naproxen 
diminished inflammatory pain by 41.6%, which is even 
less than our finding in the formalin test during phases 1 
and 2 (72.2 and 70%, respectively; p ≤0.05 vs. formalin 
5%; see figures 2 and 3). Liang and colleagues (2013) 
proposed that the anti-inflammatory activity of eugenol is 
similar to that of naproxen and exhibits less ulcerogenic 
activity. In addition, they synthesized a prodrug denoted as 
the naproxen eugenol ester, with good anti-inflammatory 
results and fewer adverse reactions. Zhao and colleagues 
(2005) proposed a formulation of ibuprofen–eugenol ester 
as an oral suspension with promising effects in the field 
of analgesia and inflammation, which is in agreement 
with our findings of a more marked activity of eugenol 
in phase 2. 
Tramadol conferred a 1.75 and 1.66 times greater 
phase 1 and 2 effect, respectively, than eugenol. It 
diminished the behavior by 66% and nearly 77.7% in 
phase 1, and 80% of phase 2, in the formalin test for 
eugenol (p ≤0.05 vs. formalin 5%) in our study; see 
figures 2 and 3. It appears, according to other studies, that 
eugenol presents an antinociceptive effect that can be due 
to central and peripheral control mechanisms (Kurian et 
al., 2006), which can be mediated by adrenergic α2, opioid 
(but not serotoninergic) mechanisms (Park et al., 2011), 
glutamatergic receptors (kainate and AMPA), inhibition 
of TNF-α (Dal Bó et al., 2013), calcium channel and 
vanilloid receptor modulation (Kurian et al., 2006), and 
in neuropathic pain, the antinociceptive effect is provided 
by N-methyl-D- aspartate receptors (NMDAr) (Aoshima, 
Hamamoto, 1999). However, eugenol does not have a 
similar effect to that of tramadol at the dose employed.
Despite the scientific evidence and experience in 
the use of eugenol, no total acceptance for its use has been 
achieved. Notwithstanding this, in the dental area, it has 
been utilized (Fucks, Peretz, 2016; Escobar-Garcia et al., 
2016). An example of this is pulpar therapy in temporary 
dentition (González-Lara et al., 2014). Other studies argue 
about the toxic effects in certain cellular types, such as 
that reported by Escobar-Garcia and colleagues (2016), 
in which the authors assert that different concentrations of 
eugenol produce high toxicity in dental pulp fibroblasts in 
temporary dentition. 
On the other hand, eugenol has been shown to have 
anti-cancerogenic properties. It is widely used in the 
treatment of dental caries and periodontal diseases, and it 
has been shown to diminish allergic asthma and produce 
anticonvulsant and anti-stress activities (Kurian et al., 
2006).
With the experimental evidence, it is clear that 
eugenol (4-allyl-2-methoxyphenol) has considerable 
potential from the viewpoint of inflammatory pain in 
models such as that of formalin. The data substantiate 
the empirical knowledge of its use, complement the 
experience of its employment in the clinic, and can support 
its use in natural therapy as an option with a scientific 
rationale. 
CONCLUSION
The data suggest that eugenol possesses moderate 
antinociceptive activity in acute pain and more activity 
in inflammatory-type pain (phase 1 and 2 of the formalin 
test) at the doses employed. Both effects are comparable 
to those produced by diclofenac but inferior to the effects 
produced by naproxen and tramadol in the formalin model.
CONFLICT OF INTEREST
All authors declare no competing interests.
ACKNOWLEDGEMENTS
This investigation was supported by PRODEP 
(UASLP-CA-245), UASLP C18-FAI-05-50.50, UASLP 
C18-FAI-05-72.72 and PFCE-UASLP grants.
REFERENCES 
Aoshima H, Hamamoto K. Potentiation of GABAA receptors 
expressed in Xenopus oocytes by perfume and phytoncid. Biosci 
Biotechnol Biochem. 1999;63(4):743-8.
D. E. Lugo-Lugo, A. J. Pozos-Guillén, J. R. Zapata-Morales, A. Rodríguez-Chong, A. J. Rangel-López, M. Z. Saavedra-Leos, A. A. Vértiz-Hernández
Braz. J. Pharm. Sci. 2019;55:e18022Page 6 / 7
Apparecido ND, Sartoretto SM, Schmidt G, Caparo SM, 
Bersani CA, Cuman RK. Anti-inflammatory and antinociceptive 
activities of Eugenol essential oil in experimental animal 
models. Braz J Pharmacogn. 2009;19(1B):212-217.
Charan-Raja MR, Srinivasan V, Selvaraj S, Kar-Mahapatra S. 
Versatile and synergistic potential of eugenol: A Review. Pharm 
Anal Acta. 2015;6(5):1-6.
Dal Bó D, Luiz PA, Martins DF, Mazzardo-Martins L, Santos 
AR. Eugenol reduces acute pain in mice by modulating the 
glutamatergic and Tumor Necrosis Factor alpha (TNF-α) 
pathways. Fund Clin Pharmacol. 2013;27(5):517-525.
Escobar-García M, Rodríguez Contreras K, Ruíz-Rodríguez S, 
Pierdant-Pérez M, Cerda-Cisterna B, Pozos-Guillen AJ. Eugenol 
toxicity in human dental pulp fibroblasts of primary teeth. J Clin 
Pediat Dent. 2016;40(4)312-318.
Faezeh V, Rezae R, Saegara H, Hashemzaei M, Shirani K, 
Karimi G. Effects of silymarin on neuropathic pain and 
formalin induced nociception in mice. Iran J Basic Med Sci. 
2015;18(7):715-720.
Fuks AB, Peretz B. Current concepts in pulp therapy for primary 
and young permanent teeth. In: Pediatric Endodontics. Suiza: 
Springer International Publishing; 2016, p 52-68. 
García de Alba-García JE, Ramírez-Hernández BC, Robles-
Arellano G, Zañudo-Hernández J, Salcedo-Rocha AL, García 
de Alba-Verduzco JE. Conocimiento y uso de las plantas 
medicinales en la zona metropolitana de Guadalajara. Desacatos. 
2012;39:29-44. 
González-Lara A, Ruiz-Rodríguez MS, Pierdant-Pérez M, 
Garrocho-Rangel JA, Pozos-Guillén AJ. Zinc oxide-eugenol 
pulpotomy in primary teeth 2: A 24-month follow-up. J Clin 
Pediatr Dent. 2016:40(2):107-112. 
Hasani A, Soljakova M, Jakupi M, Ustalar OS. Preemptive 
analgesic effects of Midazolam and Diclofenac in rat model. 
Bosnian J Basic Med Sci. 2011;11(2):113-118.
Hu D, Arocha A, Pineda AM. Alternativas de tratamiento desde 
la medicina natural y bioenergética en enfermedades sistémicas 
y sus manifestaciones bucales. 2014, p. 2-12. [Accessed 23 Feb 
2016]. Available at: http://www.morfovirtual2014.sld.cu/index.
php/Morfovirtual/2014/paper/download/297/193.
International Association for the Sutdy of Pain. IASP-PAIN.ORG 
[Internet]. Washington, DC, USA: 1973 [updated January 20, 
2014; aforementioned: September 13 2016]. Available at: www.
iasp-pain.org/Education/Content.aspx?ItemNumber=1217.
Kong X, Liu X, Li J, Yang Y. Advances in pharmacological 
research of eugenol. Curr Opin Complem Alternat Med. 
2014:1(1):8-11.
Kurian R, Arulmazhi DK, Veeranjaneyulu A, Bodhankar SL. 
Effects of Eugenol on animal models of nociception. Indian J 
Pharmacol. 2006;38(5):341-345.
Liang D, Yang X, Sun W, Wang W, Yang J, Liu Y, et al. Synthesis, 
crystal structure and biological activities of Naproxen-Eugenol 
ester prodrug. Chem Res Chin Univ. 2013;29(2):245-248.
Mendoza S, Noa M, Valle M, Mendoza N, Mas R. Effects 
of D-002 on formaldehyde-induced osteoarthritis in rats. 
IOSRPHR J Pharm. 2013;3(7):09-12.
Morales B. Alternativas de tratamiento para la osteítis alveolar 
(alveolo seco) y revisión de la literatura. Rev Asociac Dental 
Mexicana ADM. 2011;28(6):278-282.
Murakami Y, Kawata A, Seki Y, Koh T, Yuhara K, Maruyama 
T, et al. Comparative inhibitory effects of Magnolol, Honokiol, 
Eugenol and Bis-Eugenol on cyclooxygenase-2 expression and 
nuclear factor-kappa B activation in RAW264.7 macrophage-
like cells stimulated with fimbriae of Porphyromonas 
gingivalis”. In Vivo. 2012;26(6):941-950.
Organización Mundial de la Salud. Sobre el tratamiento 
farmacológico del dolor persistente en niños con enfermedades 
médicas. OMS Organización Mundial de la Salud; 2012.
Park SH, Sim YB, Lee JK, Kim SM, Kang YJ, Jung JS, et al. 
The analgesic effects and mechanisms of orally administered 
eugenol. Arch Pharm Res. 2011;34(3):501-507.
Pavithra B. Eugenol- A Review. IJPSR Int J Pharm Sci Res. 
2014;6(3):153-154. 
Picazo A, Castañeda-Hernández G, Ortiz M. Examination of the 
interaction between peripheral Diclofenac and Gabapentin on 
the 5% formaline test in rats. Life Sci. 2006;79(24):2283-2287.
Raghavendra RH, Naidu KA. Spice active principles as the 
inhibitors of human platelet aggregation and thromboxane 
biosynthesis. Prostaglandins Leukotrienes Essential Fatty Acids. 
2009;81(1):73-78. 
Antinociceptive local activity of 4-allyl-1-hydroxy-2-methoxybenzene (eugenol) by the formalin test: an anti-inflammatory effect
Braz. J. Pharm. Sci. 2019;55:e18022 Page 7 / 7
Yano S, Suzuki Y, Yuzurihara M, Kase Y, Takeda S, Watanabe 
S, et al. Antinociceptive effect of Methyleugenol on formalin-
induced hyperalgesia in mice. Eur J Pharmacol. 2006;553(1-
3):99-103. 
Zhao XL, Chen P, Gao DW, Luo YF, Li KX. Synthesis, 
properties and microemulsion formulation of Ibuprofen Eugenol 
ester. Pharmazie. 2005;60(12):883-887.
Received for publication on 08th January 2018
Accepted for publication on 19th April 2018
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
